Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06644443 | BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT04070040 | Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) | recruiting | Phase 2 | 21 | Beijing Sanbo Brain HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05299424 | A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 48 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06635330 | Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL | recruiting | Phase 1 / Phase 2 | 5 | Kara Yakhteh Tajhiz Azma CompanyNETWORK | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06633341 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06418477 | Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD | recruiting | Phase 2 | 20 | Peking University People's HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT04638790 | First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)(HL-Russia-1) | recruiting | Phase 3 | 300 | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaOTHER | 2 | Sep 27, 2024 | clinicaltrials |
| NCT06238648 | Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | recruiting | Phase 2 | 120 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06615193 | A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor | recruiting | Phase 1 | 111 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06581640 | Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | Phase 2 | 5 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06598722 | BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma. | recruiting | Phase 2 | 206 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT05641428 | Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL(HOVON161) | recruiting | Phase 2 | 300 | University Medical Center GroningenOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT04332822 | A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma(POLAR BEAR) | recruiting | Phase 3 | 300 | Nordic Lymphoma GroupNETWORK | 7 | Sep 19, 2024 | clinicaltrials |
| NCT06073938 | Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement | recruiting | — | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06503263 | Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL | recruiting | Phase 2 | 240 | Navy General Hospital, BeijingOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06532643 | Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma | recruiting | Early Phase 1 | 9 | Shanghai First Song Biotechnology Co., LTDINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06539832 | Intestinal Flora and Immunity in Monoclonal Gammopathy Patients | recruiting | — | 300 | Zhujiang HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06592170 | Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)(MZL-001) | recruiting | Phase 1 / Phase 2 | 35 | The First Hospital of Jilin UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06593145 | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms(CARLA) | recruiting | Phase 1 | 6 | FamiCordTxINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06341556 | A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma | recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT06553352 | Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma | recruiting | Phase 2 | 39 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06047197 | Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 25 | Beijing Yongtai Ruike Biotechnology Company LtdINDUSTRY | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06569485 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients | recruiting | Phase 2 | 38 | Sun Yat-sen UniversityOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT04838652 | Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma(Pembro-CORE) | recruiting | Phase 2 | 29 | University of CologneOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT02131753 | Therapy Optimisation for the Treatment of Hairy Cell Leukemia | recruiting | Phase 2 / Phase 3 | 210 | University of GiessenOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05255354 | Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy | recruiting | — | 300 | Adaptive BiotechnologiesINDUSTRY | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06566807 | Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 51 | Huai'an First People's HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06479356 | CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma | recruiting | Phase 2 | 12 | Shanghai Ming Ju Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06187441 | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)(HOVON174MM) | recruiting | Phase 3 | 599 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06541327 | Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection | recruiting | — | 1,000 | Ruijin HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06554561 | A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 1 / Phase 2 | 43 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06541860 | DAratumumab and REvlimid REfractory MM | recruiting | — | 100 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06522555 | The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | recruiting | Phase 3 | 100 | Ruijin HospitalOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06271252 | A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | recruiting | Phase 1 | 81 | OriCell Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06508099 | Vitamin A and D Supplementation in Allogeneic HCT(VitaStem) | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06478472 | Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy | recruiting | N/A | 36 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT04837859 | Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma(INDIE) | recruiting | Phase 2 | 120 | University of CologneOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06520176 | Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients | recruiting | Phase 3 | 99 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Jul 25, 2024 | clinicaltrials |
| NCT06521255 | Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 3 | 244 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 25, 2024 | clinicaltrials |
| NCT04014374 | Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab | recruiting | — | 150 | Kyowa Kirin, Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06517004 | An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | recruiting | Phase 1 | 9 | Fudan UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06515262 | Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | recruiting | N/A | 10 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06287398 | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | recruiting | Phase 2 | 39 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06513234 | Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas | recruiting | Phase 2 | 45 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06505369 | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients(TALTEC) | recruiting | Phase 2 | 50 | North Estonia Medical CentreOTHER | 3 | Jul 17, 2024 | clinicaltrials |
| NCT06503107 | Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM | recruiting | Phase 1 / Phase 2 | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06496308 | Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment | recruiting | Phase 3 | 78 | Ruijin HospitalOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT06494371 | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | recruiting | Phase 1 | 32 | Ruijin HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05636787 | Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients(TreoMel) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Jul 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Oct 16, 2024source: clinicaltrials